Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antiviral Agents
/ pharmacology
COVID-19
/ blood
Chlorocebus aethiops
High-Throughput Screening Assays
Humans
Neutralization Tests
/ methods
SARS-CoV-2
/ drug effects
Vero Cells
Viral Plaque Assay
Virus Replication
/ drug effects
Antivirals
COVID-19
Monoclonal antibodies
Neutralization
Neutralizing antibodies
Plaque reduction microneutralization assay
Polyclonal antibodies
SARS-CoV-2
Journal
Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
04
10
2020
revised:
07
10
2020
accepted:
10
10
2020
pubmed:
18
10
2020
medline:
22
12
2020
entrez:
17
10
2020
Statut:
ppublish
Résumé
Towards the end of 2019, a novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), genetically similar to severe acute respiratory syndrome coronavirus (SARS-CoV), emerged in Wuhan, Hubei province of China, and has been responsible for coronavirus disease 2019 (COVID-19) in humans. Since its first report, SARS-CoV-2 has resulted in a global pandemic, with over 10 million human infections and over 560,000 deaths reported worldwide at the end of June 2020. Currently, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines and/or antivirals licensed against SARS-CoV-2. The high economical and health impacts of SARS-CoV-2 has placed global pressure on the scientific community to identify effective prophylactic and therapeutic treatments for SARS-CoV-2 infection and associated COVID-19 disease. While some compounds have been already reported to reduce SARS-CoV-2 infection and a handful of monoclonal antibodies (mAbs) have been described that neutralize SARS-CoV-2, there is an urgent need for the development and standardization of assays which can be used in high through-put screening (HTS) settings to identify new antivirals and/or neutralizing mAbs against SARS-CoV-2. Here, we described a rapid, accurate, and highly reproducible plaque reduction microneutralization (PRMNT) assay that can be quickly adapted for the identification and characterization of both neutralizing mAbs and antivirals against SARS-CoV-2. Importantly, our MNA is compatible with HTS settings to interrogate large and/or complex libraries of mAbs and/or antivirals to identify those with neutralizing and/or antiviral activity, respectively, against SARS-CoV-2.
Identifiants
pubmed: 33068703
pii: S0166-0934(20)30247-0
doi: 10.1016/j.jviromet.2020.113995
pmc: PMC7554492
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113995Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Nat Commun. 2016 May 10;7:11544
pubmed: 27161536
Sci Rep. 2018 Mar 12;8(1):4374
pubmed: 29531320
Front Microbiol. 2019 Apr 12;10:718
pubmed: 31031722
BMJ. 2020 Apr 22;369:m1610
pubmed: 32321732
Adv Virus Res. 2006;66:193-292
pubmed: 16877062
Am J Emerg Med. 2020 May 6;:
pubmed: 32402498
mBio. 2019 Mar 12;10(2):
pubmed: 30862743
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Virology. 2015 Feb;476:206-216
pubmed: 25553516
J Virol. 2014 Jan;88(2):878-89
pubmed: 24198417
J Virol. 2011 Feb;85(4):1684-95
pubmed: 21123370
J Virol. 2019 Nov 13;93(23):
pubmed: 31511388
J Travel Med. 2020 Mar 13;27(2):
pubmed: 31985790
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
J Virol. 2020 Mar 17;94(7):
pubmed: 31941776
CMAJ. 2020 Apr 27;192(17):E450-E453
pubmed: 32269021
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
J Vis Exp. 2017 Sep 7;(127):
pubmed: 28930978
Springer Semin Immunopathol. 1997;18(3):371-90
pubmed: 9089955
Oncotarget. 2017 Feb 21;8(8):12686-12694
pubmed: 27050368
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
J Transl Med. 2020 May 5;18(1):185
pubmed: 32370758
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91
pubmed: 8278823
mBio. 2020 May 22;11(3):
pubmed: 32444382
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
ACS Chem Biol. 2013 Nov 15;8(11):2501-8
pubmed: 23978130
J Med Toxicol. 2020 Jul;16(3):284-294
pubmed: 32356252
J Biopharm Stat. 2016;26(3):409-20
pubmed: 26010892
FEBS Lett. 2004 Oct 8;576(1-2):174-8
pubmed: 15474033
J Virol. 2018 Jul 31;92(16):
pubmed: 29875238
Vaccine. 2015 Jul 9;33(30):3562-70
pubmed: 26044496
J Virol. 2010 Feb;84(4):2157-63
pubmed: 19939917
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
Virus Res. 2016 Feb 2;213:69-81
pubmed: 26590325
J Virol. 2019 May 1;93(10):
pubmed: 30867298
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
N Engl J Med. 1988 Jan 7;318(1):1-6
pubmed: 3336379